US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Outlook Therapeutics Inc (OTLKW)
Outlook Therapeutics Inc (OTLKW) ニュース

OTLKW

Outlook Therapeutics (OTLKW)

Outlook Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OTLKW

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/11	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/05/28	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/05/16	06 : 00	GlobeNewswire Inc.	Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/05/13	21 : 50	GlobeNewswire Inc.	Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/05/09	21 : 45	GlobeNewswire Inc.	Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/05/02	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the Retina World Congress 2024	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/04/29	22 : 00	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/04/16	05 : 15	GlobeNewswire Inc.	Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/03/22	20 : 35	GlobeNewswire Inc.	Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/03/19	06 : 10	GlobeNewswire Inc.	Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/03/12	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/02/14	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/01/31	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Doses First Subject in NORSE EIGHT	NASDAQ:OTLKW	Outlook Therapeutics Inc
2024/01/23	22 : 00	GlobeNewswire Inc.	Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/12/22	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/12/19	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/12/06	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Announces Strategic Organizational Realignment	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/11/27	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/11/14	22 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/11/02	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Provides Update on Type A Meetings with FDA	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/11/01	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/09/29	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Requests Type A Meeting With FDA	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/09/21	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/09/05	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/08/30	19 : 00	GlobeNewswire Inc.	Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/08/14	21 : 05	GlobeNewswire Inc.	Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/08/01	21 : 45	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/05/16	20 : 10	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/05/16	19 : 06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OTLKW	Outlook Therapeutics Inc
2023/05/16	05 : 51	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OTLKW	Outlook Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:OTLKW

1 2 3 4 5 6 7 8 9 次へ >>

US Dollar vs Yen

US Dollar vs Sterling

Financial Select Sector

US Dollar vs Euro

Deutsche Telekom (QX)

BNP Paribas (QX)

Gold vs US Dollar

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約